# Phase 3 lymphoma trials recruiting: 77 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 77 trials in phase 3 for lymphoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 lymphoma trials: 77 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/lymphoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 77
- Recruiting or not yet: 77
- Read on: November 19, 2026

## Trials

The 25 newest of 77, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 2, 2026 | NCT07911553 | A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to \< 80 Years of Age With Previously Untreated Large B-cell... | AstraZeneca | Phase 3 | Not yet recruiting | Large B-cell Lymphoma | 1,200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911553) |
| October 27, 2026 | NCT07896590 | Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 3 | Not yet recruiting | Relapsed/Refractory Marginal Zone Lymphoma (MZL) | 292 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896590) |
| September 9, 2026 | NCT07808827 | A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients... | Shanghai Junshi Bioscience Co., Ltd. | Phase 3 | Recruiting | Diffuse Large B-Cell Lymphoma | 282 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07808827) |
| August 25, 2026 | NCT07784101 | A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or... | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 3 | Not yet recruiting | Relapsed or Refractory Mantle Cell Lymphoma (MCL) | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07784101) |
| August 10, 2026 | NCT07754682 | Immunoglobulin Replacement Therapy (IgRT) Versus Antibiotic Prophylaxis (PA) in Patients Treated by CD19-targeted Chimeric Antigen Receptor... | Assistance Publique - Hôpitaux de Paris | Phase 3 | Not yet recruiting | Chimeric Antigen Receptor T-cell Therapy, B Cell Acute Lymphoblastic Leukemia (B-ALL), B Cell Lymphoma, Antibiotic... | 228 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07754682) |
| July 31, 2026 | NCT07739654 | Modified DHAP Versus Standard DHAP in Relapsed/Refractory Diffused Large B-cell Lymphoma. | King Edward Medical University | Phase 3 | Recruiting | DLBCL - Diffuse Large B Cell Lymphoma | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07739654) |
| July 30, 2026 | NCT07736950 | A Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without Rituximab in Adults With Limited Stage Nodal... | Australasian Leukaemia and Lymphoma Group | Phase 3 | Not yet recruiting | Follicular Lymphoma | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07736950) |
| July 22, 2026 | NCT07719855 | A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide... | Ruijin Hospital | Phase 3 | Not yet recruiting | Follicular Lymphoma ( FL) | 652 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07719855) |
| July 1, 2026 | NCT07678229 | BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL | Sponsor not shown (see the record) | Phase 3 | Recruiting | Extranodal NK/T-cell Lymphoma | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07678229) |
| June 26, 2026 | NCT07671248 | Tirzepatide in the Treatment of Cannabis Use Disorder | McMaster University | Phase 3 | Not yet recruiting | Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07671248) |
| June 15, 2026 | NCT07648264 | Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting... | CSL Behring | Phase 3 | Recruiting | Secondary Immune Deficiency | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07648264) |
| June 10, 2026 | NCT07639879 | TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma | Tarapeutics Science Inc. | Phase 3 | Not yet recruiting | PTCL, NK T-Cell Lymphoma | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07639879) |
| May 12, 2026 | NCT07582432 | A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency... | Grifols Biologicals, LLC | Phase 3 | Recruiting | Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07582432) |
| May 1, 2026 | NCT07562022 | A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular... | Sinocelltech Ltd. | Phase 3 | Recruiting | Follicular Lymphoma (FL) | 93 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07562022) |
| April 7, 2026 | NCT07516093 | Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL | Nurix Therapeutics, Inc. | Phase 3 | Recruiting | B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 620 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07516093) |
| April 3, 2026 | NCT07509151 | Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated... | AstraZeneca | Phase 3 | Recruiting | Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07509151) |
| March 25, 2026 | NCT07493109 | Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP | Sponsor not shown (see the record) | Phase 3 | Recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07493109) |
| March 17, 2026 | NCT07476729 | International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) | Charite University, Berlin, Germany | Phase 3 | Recruiting | B-Cell Acute Lymphoblastic Leukaemia | 750 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07476729) |
| February 17, 2026 | NCT07414758 | Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 3 | Recruiting | Peripheral T Cell Lymphoma | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07414758) |
| February 13, 2026 | NCT07409428 | A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL | Hutchmed | Phase 3 | Recruiting | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07409428) |
| January 30, 2026 | NCT07377578 | A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma | Guangzhou Lupeng Pharmaceutical Company LTD. | Phase 3 | Recruiting | Mantle Cell Lymphoma | 394 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07377578) |
| January 21, 2026 | NCT07355283 | IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular... | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Phase 3 | Not yet recruiting | Relapsed/Refractory Follicular Lymphoma | 198 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07355283) |
| December 23, 2025 | NCT07300514 | Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma | Fudan University | Phase 3 | Recruiting | Maintenance Treatment of Peripheral T-cell Lymphoma | 136 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07300514) |
| November 18, 2025 | NCT07234162 | A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) | Dizal Pharmaceuticals | Phase 3 | Recruiting | Peripheral T-cell Lymphoma | 218 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07234162) |
| October 31, 2025 | NCT07223021 | A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia | Memorial Sloan Kettering Cancer Center | Phase 3 | Recruiting | B-cell Acute Lymphoblastic Leukemia | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07223021) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Ruijin Hospital | 4 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 3 |
| Alliance for Clinical Trials in Oncology | 3 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 3 |
| Assistance Publique - Hôpitaux de Paris | 3 |
| [Beijing InnoCare Pharma Tech Co., Ltd.](https://specstream.ai/data/clinical-trials/company/beijing-innocare-pharma-tech-co-ltd) | 3 |
| Memorial Sloan Kettering Cancer Center | 2 |
| Fondazione Italiana Linfomi - ETS | 2 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 2 |
| Shanghai Junshi Bioscience Co., Ltd. | 1 |
| Fudan University | 1 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 1 |
| Loxo Oncology, Inc. | 1 |
| Nuvation Bio Inc. | 1 |
| Australasian Leukaemia and Lymphoma Group | 1 |
| Stichting Hemato-Oncologie voor Volwassenen Nederland | 1 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 1 |
| The Lymphoma Academic Research Organisation | 1 |
| St. Louis University | 1 |
| [Grifols Therapeutics LLC](https://specstream.ai/data/clinical-trials/company/grifols-therapeutics-llc) | 1 |
| [Chengdu Zenitar Biomedical Technology Co., Ltd](https://specstream.ai/data/clinical-trials/company/chengdu-zenitar-biomedical-technology-co-ltd) | 1 |
| Lyell Immunopharma, Inc. | 1 |
| [Sinocelltech Ltd.](https://specstream.ai/data/clinical-trials/company/sinocelltech-ltd) | 1 |
| Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 1 |
| Mayo Clinic | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 34 |
| United States | 28 |
| Italy | 18 |
| France | 16 |
| Australia | 15 |
| Canada | 15 |
| Germany | 15 |
| Spain | 14 |
| United Kingdom | 13 |
| Poland | 13 |
| South Korea | 10 |
| Belgium | 10 |
| Turkey (Türkiye) | 10 |
| Brazil | 9 |
| Taiwan | 8 |
| Czechia | 8 |
| Israel | 7 |
| Netherlands | 7 |
| Sweden | 6 |
| Austria | 6 |
| Hungary | 6 |
| Japan | 6 |
| Denmark | 6 |
| Puerto Rico | 5 |
| Chile | 5 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Internet marketing agencies in the United States](https://specstream.ai/data/businesses/internet-marketing-agencies/united-states)
- [Courier and delivery companies in the United States](https://specstream.ai/data/businesses/courier-and-delivery-companies/united-states)
- [Wine bars in the United States](https://specstream.ai/data/businesses/wine-bars/united-states)
- [Portuguese restaurants in the United States](https://specstream.ai/data/businesses/portuguese-restaurants/united-states)
- [Hospitals in the United States](https://specstream.ai/data/businesses/hospitals/united-states)
- [Civil engineering firms in the United States](https://specstream.ai/data/businesses/civil-engineering-firms/united-states)
